• Users Online: 318
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
Year : 2016  |  Volume : 5  |  Issue : 4  |  Page : 143-145

An introduction to pharmacovigilance: what a cardiologist must know

Takeda Development Centre Europe Ltd., United Kingdom

Correspondence Address:
Sumit Munjal
Takeda Development Centre Europe Ltd., 61, Aldwych, London, WC2B 4AE
United Kingdom
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/2250-3528.192698

Rights and Permissions

The science of pharmacovigilance (PV) is important to ensure safety of patients and healthy volunteers taking medicinal products. A number of stakeholders are involved who contribute to the success of this field of medicine. One such contributor is physicians and health-care professionals who work in different therapeutic areas such as cardiology. As the understanding of this science evolves, the role of cardiologist becomes even more vital. The process of developing drugs is getting more complex, time consuming, and costly. However, several efficiencies can be achieved around accelerated drug development, cost effectiveness, risk management, managing health authority expectations, and developing personalized medicines. This is possible by increased collaboration between cardiologists and pharmaceutical medicine professionals. Therefore, it is important for a cardiologist to understand the basics of the science of PV and contribute further bringing new safe medicines to patients.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded269    
    Comments [Add]    

Recommend this journal